Solvias to Present Groundbreaking Insights on Gene Therapy Safety at ASGCT 2025 At ASGCT 2025, Solvias will unveil innovative approaches to enhancing safety in gene therapy development, particularly focusing on lentiviral vectors.

Solvias to Present Groundbreaking Insights on Gene Therapy Safety at ASGCT 2025 #United_States #New_Orleans #gene_therapy #Lentiviral_Vector #Solvias

VIVEbiotech Partners with Ampersand Capital for Growth in Lentiviral Vector Manufacturing VIVEbiotech announces a significant investment from Ampersand Capital Partners aimed at boosting lentiviral vector production capacity to meet rising demands in gene therapy.

VIVEbiotech Partners with Ampersand Capital for Growth in Lentiviral Vector Manufacturing #Spain #Ampersand_Capital #VIVEbiotech #Lentiviral_Vector #San_Sebastián